Kornimate/medical-research-clean huggingface dataset:
photodynamic therapy in treatment of verrucae

Conditions: Verruca Vulgaris

Summary: to assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with ipl versus ipl only in treatment of warts.

this study will be conducted on: eighty patients suffering of verruca (male and female) divided randomly into three groups: group a, b\&c : group a: 30 patients will undergo photodynamic therapy using intralesional 4%methylene blue solution and ipl. group b: 30 patients will undergo ipl only. group c (control group):20 patients will undergo intralesional saline.

Eligibility criteria:
inclusion criteria: 1. age:above 16 years old. 2. sex:both males and female patients. 3. clinically and dermoscopically documented verruca. 4. no verruca treatment in the last 2 weeks. exclusion criteria: 1. history of photosensitivity disorder. 2. pregnant and lactating females. 3. diseases with risk of koebnerization e.g. psoriasis and lichen planus. 4. anogenital warts. 5. warts on head and neck.
prospective, non-interventional, multi-center, post-authorization safety study of riociguat for pulmonary arterial hypertension (pah)

Conditions: Hypertension, Pulmonary

Summary: the primary objective in this study is to collect post-marketing information on riociguat safety.thus, the information on adverse events (aes) and adverse drug reactions (adrs) that occur within the first 12 months and in the following 6 -year observation at most, after starting riociguat treatment under the routine clinical practice will be collected. the secondary objectives are collecting information on riociguat effectiveness, such as 6-minute walking distance (6mwd) test. since it is assumed that riociguat is for long-term use, information on pulmonary arterial hypertension (pah) clinical worsening will also be surveyed once a year.

this local, prospective, non-interventional, multi-center study includes patients treated with riociguat for pah. a total of 600 patients (valid for safety analysis) is planned to be included in 4 years. this study is performed as an "all-case investigation" therefore; all patients who receive riociguat treatment for pah need to be registered, in principle. the treatment should be performed based on the product label in japan. the standard observation period will last for 12 months from starting riociguat treatment. safety and effectiveness will be evaluated at the 3rd and 12th month of treatment. in addition, the extension observation period will be carried out as long as riociguat treatment continues or at most for more 6 years. the purpose is to collect information on safety and effectiveness, such as adverse events and clinical worsening of pah, once a year. combining the standard observation and the extension observation period the patient could be followed for at most 7 years. when riociguat treatment is terminated, the observation of the patient ends. the investigator should record data for each patient, as defined in the protocol, using the electronic data capture (edc) system. the duration of the study is of approximately 8 years from pah indication approval.

Eligibility criteria:
inclusion criteria: * patients who are treated with riociguat for pah exclusion criteria: * n/a

Keywords: riociguat adempas soluble guanylate cyclase (sgc) stimulator pulmonary arterial hypertension japan post-marketing surveillance
nasal vs. oral intubation for neonates requiring cardiac surgery

Conditions: Congenital Heart Disease; Oral Aversion

Summary: often, infants struggle to feed orally after surgery for congenital heart disease and may require supplemental feeding interventions at discharge. in this study, the investigators prospectively randomize infants to oral or nasal endotracheal intubation for surgery and assess postoperative feeding success.

patients who require cardiac surgery in the neonatal period frequently encounter difficulties reaching full volume oral feeds. these difficulties are related to developmental features, perioperative events, and post-operative oral aversion symptoms. patients who struggle with oral feeding require longer hospitalizations and frequently require invasive devices for stable nutrition at discharge. the investigators hypothesize that nasal intubation for neonatal cardiac surgery may reduce time to full oral feeds and decrease the proportion of patients requiring discharge feeding tubes. this is a single-center, prospective randomized control trial of patients less than 2 weeks of age who undergo endotracheal intubation at the time of cardiac surgery. the investigators exclude patients who were \ 5 days of intubation before surgery, or required ecmo or \>5 minutes of cpr at any time during the hospitalization. patients are randomized to nasal (ni) or oral intubation (oi) by a trained pediatric cardiac anesthesiologist at the time of their surgery. infants are followed post-operatively until the time of discharge and otherwise receive routine care in the intensive care unit and acute cardiology service. information regarding feeding milestones is obtained from the electronic medical record.

Eligibility criteria:
inclusion criteria: * infants who require surgery for congenital heart disease before 2 weeks of age exclusion criteria: * \< 37 weeks estimated gestational age at the time of surgery * orofacial or gastrointestinal anomalies * devastating neurologic injury or malformation * intubation \> 5 days prior to surgery * \> 5 minutes of cpr or ecmo at any time
adsc injections for pain management of osteoarthritis in the human knee joint

Conditions: Osteoarthritis of the Knee

Summary: this safety and feasibility study used autologous adipose-derived stromal cells (adsc), the stromal vascular fraction (svf), to treat 8 osteoarthritic (oa) knees in 6 patients of grade i to iii (k-l scale) with initial pain of 4 or greater on a 10 point scale, under institutional review board (irb) approved protocol.

this safety and feasibility study used autologous adipose-derived stromal cells, the stromal vascular fraction, to treat 8 osteoarthritic knees in 6 patients of grade i to iii (k-l scale) with initial pain of 4 or greater on a 10 point scale, under irb-approved protocol. evaluation of the safety of intra-articular injection of the stromal vascular fraction cells was the primary objective of the study. adipose-derived stromal vascular cells were obtained through enzymatic disaggregation of lipoaspirate, resuspended in 3 ml of lactated ringer's solution, and injected directly into the intra-articular space with a mean of 12 million viable nucleated svf cells per knee.

Eligibility criteria:
inclusion criteria: * voluntarily provided written informed consent * ages 20-70 * male or female * grades i-iii radiologically documented oa of one or both knees * american society anaesthesiologists (asa) physical status class i-ii and a • bmi less than 35 * knee pain graded as greater than 3 out of 10 on screening questionnaire * able to speak, read and understand english - exclusion criteria: * patient parameters falling outside of the inclusion criteria * current oral or parenteral steroid or blood thinner use * hyaluronic acid-based injection to the affected knee joint within the previous six months * corticosteroid injection to the affected knee joint within the previous three months * end stage (grade iv) oa

Keywords: adsc osteoarthritis knee adipose
transcriptomic evaluation of endometrial receptivity

Conditions: Infertility, Female

Summary: the purpose of this study is to comprehensively evaluate the transcriptomic signal of the endometrium before, during, and after the window of receptivity.

phase 1 will aim to define a normal endometrial transcriptomic signature in healthy controls without infertility. phase 2 will elucidate endometrial transcriptomic expression in patients with diagnoses of infertility unrelated to endometrial factor. findings from this phase will be compared to the results of phase 1.

Eligibility criteria:
phase 1: major inclusion: the following are major inclusion criteria: 1. regular menstrual cycles 2. age 18-50 3. normal baseline ultrasound 4. no intrauterine procedures in prior 90 days exclusions: the following are exclusion criteria: 1. any contraindications to undergoing estrogen stimulation of the endometrium 1. current smoking status 2. multiple risk factors for arterial cardiovascular disease (smoking, diabetes, and hypertension) 3. hypertension (systolic ≥140 mmhg or diastolic ≥90 mmhg) 4. venous thromboembolism (current or history of) 5. known thrombogenic mutations 6. known ischemic heart disease 7. history of stroke 8. complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis) 9. systemic lupus erythematosus (positive or unknown antiphospholipid antibodies) 10. migraine with aura at any age 11. breast cancer 12. cirrhosis 13. hepatocellular adenoma or malignant hepatoma 2. history of infertility diagnosis 3. history of undiagnosed abnormal uterine bleeding. 4. allergic reaction to any medication used for the preparatory cycle 5. known pregnancy or delivery within the past 6 months 6. breastfeeding 7. obesity \>35 kg/m2 phase 2 major inclusion: the following are major inclusion criteria: 1. age 18-50 2. diagnosis of infertility with low endometrial risk 3. no intrauterine procedures in prior 90 days exclusions: in addition to the exclusion criteria for phase 1, patients deemed to have an elevated endometrial risk will also be excluded. this would include the following: 1. recurrent implantation failure 2. failed transfer with a euploid blastocyst 3. history of asherman's or abnormal endometrial function 4. history of endometriosis
avastin/folfiri in combination with curcumin in colorectal cancer patients with unresectable metastasis

Conditions: Colorectal Cancer

Summary: oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting avastin/folfiri chemotherapy for up to completion of (or withdrawal from) chemotherapy.


Eligibility criteria:
inclusion criteria: * age : 20 years and older * histologically confirmed adenocarcinoma of the colon or rectum * patients with primary colon or rectal cancer and unresectable metastatic lesions. * patients with no primary cancer related symptoms. * ecog performance status of 0 - 2 * appropriate organ functions (hepatic transaminases - less than 5 times the normal range; bilirubin - less than 2 times the normal range; creatinine serum - less than 1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than 1,500/µl) * asa score of \< 3 * an informed consent form has been signed by the patient. exclusion criteria: * colorectal cancer other than adenocarcinoma * the patient received adjuvant chemotherapy within the past 6 months. * the patient received chemotherapy for metastatic colon cancer. * the patient was planning to have curative surgery for the metastatic lesions. * patients with peritoneal carcinomatosis. * patients with primary tumor related complications such as intestinal obstruction, intractable bleeding, and perforation, that needs to be treated. * asa score of \> 4 * the patient has chronic hepatitis or cirrhosis. an asymptomatic hbv or hcv carrier can participate. * patients with an active infection, which need antibiotic therapy, during the randomization period. * pregnant or breastfeeding women * patients with another different malignant tumor during the past 5 years. patients with treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.

Keywords: curcumin avastin folfiri colorectal cancer unresectable metastasis
miswak efficacy compared with chlorhexidine

Conditions: Gingivitis

Summary: gingivitis is a form of gum disease and is elicited by the accumulation of plaque on the tooth and the soft-tissue adjoining the tooth. mouthwashes containing chemical or herbal substances are adjunctive tools in improving oral hygiene. miswak mouthwash is a herbal mouthwash. chlorhexidine mouthwash is the most efficient antimicrobial and antiplaque agent. the aim of the study is to assess the effectiveness of the miswak mouthwash with 0.12% chlorhexidine. this study was a blind randomized clinical trial. materials and methods: a total of 60 patients aged (20-55) years old who attended the periodontics clinics at college of dentistry, al-iraqia university were allocated for use the mouthwash either miswak mouthwash or 0.12% chlorhexidine gluconate kin gingival® (laboratorios kin, spain) twice daily (once in the morning and one before bedtime) for seven days. gingival, bleeding, and plaque indices were recorded at baseline and after 7 days of treatment.

gingivitis is the mildest form of gum disease and is elicited by the accumulation of plaque on the tooth and the soft-tissue adjoining the tooth. accumulation of dental biofilm has been established as the initial cause of this disease. it is determined by redness of the gum margins, edema, bleeding upon brushing, and loss of periodontal attachment loss. gingivitis exists in both acute and chronic forms. acute gingivitis is identified as trauma, micro-organisms, and specific infections while chronic inflammation is related to bacterial biofilm which covers the gum and adjoining the teeth. elimination and control of plaque are very important in the maintenance of periodontal health. chlorhexidine mouthwash has is a tremendous effect when it is used as a mouthwash for a long time; therefore, the food and drug administration (fda) recommends limiting the use of chlorhexidine mouthwash up to 6 months to minimize or limit its side effects. additionally, the world health organization (who) encouraged to consider the possible use of herb extracts and natural plants mouthwashes instead of chemical mouthwash just as miswak mouthwash. miswak mouthwash is a herbal mouthwash that is available locally and culturally accepted. it is prepared from a plant called salvadora persica which comes from a tree (arak) that grows in africa and west india.

Eligibility criteria:
inclusion criteria: * adults with existence at least 20 natural teeth in the mouth * existence of lateral maxillary teeth * existence of central teeth * existence of mandibular teeth exclusion criteria: * patients have no history of drug use * patients have no any disease relevant occurrence * pocket depth\<3 mm * smokers * pregnancy

Keywords: miswak chlorhexidine mouthwash gingivitis oral health
expanding reach of evidence-based psychotherapy for veterans with co-occurring anxiety and substance use disorders.

Conditions: Anxiety Disorders; Substance Use Disorders

Summary: the current study seeks to better understand how to improve access to evidence-based psychotherapy (ebp) for rural veterans with co-occurring anxiety and substance use disorders (sud) using a web-based cognitive behavioral therapy tool (va coordinated anxiety learning and management, substance use version; va calm-s).


Eligibility criteria:
inclusion criteria: * current anxiety disorder diagnosis * current sud exclusion criteria: * current substance withdrawal such that medically supervised detoxification is necessary (determined by evaluation of substance use history and report of current symptoms), * acute suicidality * current delusions/hallucinations.
short term efficacy of high-intensity laser therapy in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis (koa) is one of the most common health problems around the world. according to this, several interventions have been used to treat this group of patients including pharmacological and non-pharmacological management such as weight reduction, behavior modification, and physical therapy. recently, high-intensity laser therapy (hilt) has been used to treat patients with koa. the results of previous studies showed that hilt could help to reduce pain as well as improved function in patients with mild to moderate koa. however, there were still no standardized guidelines for hilt treatment in koa. also, no previous studies evaluated the efficacy of hilt in patients with severe koa. the present study, therefore, recruited not only mild to a moderate degree but also severe degree. the study aim was to determine the efficacy of hilt in terms of pain relief in patients with mild, moderate, and severe koa. the hypothesis was hilt would effectively reduce pain in patients with koa compared to sham laser plus conservative treatment.

* this study is a double-blinded randomized control trial that compared the efficacy of hplt to sham laser in patients with koa. * 42 patients who had koa diagnosed by the american college of rheumatology (acr) 2016 guidelines were recruited including a drop out of 20%. * the participants were then randomly allocated into two groups (21 participants per group), mainly hilt and sham laser. also, both groups received conservative treatment such as disease education, exercise, and advice for weight reduction. * the intervention group received hilt which was applied on the medial, lateral, and posterior part of the knee joint. the total energy was 562.5 j per session which was done 2-3 sessions a week, for a total of 10 sessions. * the control group received sham laser by the same device for 10 sessions plus conservative treatment as in the intervention group. * the outcome measures, vas and t-womac score were recorded before and at the end of the study. * statistical analysis was performed using spss 18.0 version to evaluate the statistically significant change within the same group and the difference between groups.

Eligibility criteria:
inclusion criteria: * patients with primary knee oa diagnosed based on the american college of rheumatology (acr) guidelines for early diagnosis of knee osteoarthritis 2016. * patients who had knee pain for at least 6 months and had vas score greater than 4 out of 10 points * patients with knee oa who have kellgren and lawrence (kl) classification stages 2-4. exclusion criteria: * patients who have secondary knee oa caused by other pathologies * patients who have a history of corticosteroid or hyaluronate injecting into the knee joint within the past 6 months * patients who were treated by physical therapy equipment within 1 month before the study * history of stroke, bleeding disorders, cancer, deep vein thrombosis, cognitive impairment, or mental disorders * contraindicate to laser therapy

Keywords: high-intensity, pain, knee osteoarthritis
effect of low-level laser on crevicular interleukin-1β concentration in patients with periodontal disease: a relation to periodontal inflammaging

Conditions: Periodontal Diseases; Old Age

Summary: this study is done to compare between young age and old age patients with periodontitis (inflammaging) and the effect of diode laser as adjunctive to scaling and debridement


Eligibility criteria:
inclusion criteria: 1. male or female 2. aged below 40 or above 60. 3. provide informed consent and willingness to cooperate with study protocol. 4. periodontitis stage ii patients: * cal from 3-4 mm. * radiographic bone loss (15% to 33%). * no tooth loss due to periodontitis. * maximum probing depth ≤ 5 mm, mostly horizontal bone loss exclusion criteria: 1. patients with heavy smoking habits 2. history of antibiotics in the previous three months. 3. pregnant or lactating female. 4. treatment with any systemic drug. 5. history of systemic disease. 6. patients who received periodontal treatment in the last 6 months
recombinant single-chain factor viii (rviii-singlechain) in chinese participants with hemophilia a previously treated with fviii products

Conditions: Congenital Hemophilia A

Summary: for bridging the available global clinical data of rviii-singlechain, with the chinese population, the aim of this study in china is to investigate the pharmacokinetics (pk) of rviii-singlechain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rviii-singlechain in male chinese ptps with severe hemophilia a (fviii activity less than \[\<\] 1%).


Eligibility criteria:
inclusion criteria: * male chinese participants \<= 65 years of age. * participants with severe hemophilia a (fviii activity \< 1%). * participants who have received fviii products for \>= 150 eds (\>= 6 years of age) or \>= 50 eds (\< 6 years of age). exclusion criteria: * known hypersensitivity (allergic reaction or anaphylaxis) to any fviii product or hamster protein. * known congenital or acquired coagulation disorder other than congenital fviii deficiency. * currently receiving intravenous (iv) immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment. * receiving any cryoprecipitate, whole blood, or plasma within 30 days before administration of rviii-singlechain. * use of traditional or herbal chinese medicine(s) with an impact on hemophilia, including coagulation, within 28 days before day 1 and / or refusal to abstain from these during the study until the end of the participant's participation in the study.
nudging provider adoption of clinical decision support

Conditions: Pulmonary Embolism

Summary: the central hypothesis of this proposal is that the addition of a theory-informed "nudge" to a clinical decision support (cds) tool will address identified behavioral barriers to use and significantly improve adoption by providers. nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. this study will use a behavioral theory-informed process to develop a new cds tool that includes a nudge that addresses barriers to adoption.

the research team developed and pilot tested two cds tools for pulmonary embolism (pe) risk stratification in the emergency department (ed). one of the tools incorporated two behavioral theory-informed nudges in the user interface. the research team's objective was to pilot test the tools to demonstrate feasibility as well as examine preliminary efficacy of the nudges on provider adoption of the tool. this cluster non-randomized controlled trial took place between september 20th, 2021 and march 3rd, 2022 in two eds that are a part of a large academic health system in the new york city metropolitan area. all ed providers (physicians, physician assistants and nurse practitioners) seeing patients for the evaluation of pe during this time were included in the trial. the eds were chosen based on their comparable size and acuity levels.

Eligibility criteria:
inclusion criteria: * medical doctors, nurse practitioners and physician assistants working full time at huntington hospital and long island jewish valley stream exclusion criteria: * does not meet the inclusion criteria

Keywords: clinical decision support pulmonary embolism behavioral design health informatics
study of efficacy and safety lmf237 in patients with type 2 diabetes mellitus (t2dm) inadequately controlled with vildagliptin monotherapy

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study was to evaluate the efficacy and safety of lmf237 50/250 mg and 50/500 mg bid in japanese patients with t2dm inadequately controlled with vildagliptin monotherapy. this study was conducted to support registration of the fixed-dose combination of vildagliptin and metformin for the treatment of t2dm in japan.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy * hba1c in the range of 7.0-10.0% * body mass index in the range of 20-35 kg/m\^2 exclusion criteria: * type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes * significant heart diseases other protocol-defined inclusion/exclusion criteria may apply